MECHANISM OF ACTION (MOA)

Simultaneously engages two costimulatory molecules (4-1BB and OX40) to amplify T cells’ effector function.

DIFFERENTIATING ATTRIBUTES

Stimulates pre-activated T cells locally in the tumor. Only functions when both binding domains are engaged.

MECHANISM OF ACTION (MOA)

Dual MOA designed to provide synergistic co-stimulation of CD40 on antigen presenting cells and simultaneously block the PD-1/PD-L1 inhibitory pathway

DIFFERENTIATING ATTRIBUTES

A checkpoint inhibitor with added functionality CD40 only functions when both binding domains are engaged

MECHANISM OF ACTION (MOA)

Engages CD3 on T cells which then directly kill PSMA (APVO442) or Nectin-4 (APVO455)- expressing solid tumor cells

DIFFERENTIATING ATTRIBUTES

Monovalent CD3 reduces binding to circulating T cells which enables distribution to solid tumors. T cell signaling only upon drug engagement with tumor-associated antigen (TAA).

MECHANISM OF ACTION (MOA)

Dual MOA designed to provide synergistic co-stimulation of CD40 on antigen presenting cells and stimulates T cells to directly kill Nectin-4 (APVO451) or PSMA (APVO452)-expressing  solid tumor cells

DIFFERENTIATING ATTRIBUTES

CD40 and CD3 only function when the bispecific is bound to the TAA; engages both innate and adaptive immunity.